Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy.
In 1980 the World Health Organization declared that smallpox was eradicated from the world, and routine smallpox vaccination was discontinued. Nevertheless, samples of the smallpox virus (variola virus) were retained for research purposes, not least because of fears that terrorist groups or rogue states might also have kept samples in order to develop a bioweapon. Variola virus represents an effective bioweapon because it is associated with high morbidity and mortality and is highly contagious. Since September 11, 2001, countries around the world have begun to develop policies and preparedness programs to deal with a bioterror attack, including stockpiling of smallpox vaccine. Smallpox vaccine itself may be associated with a number of serious adverse events, which can often be managed with vaccinia immune globulin (VIG). VIG may also be needed as prophylaxis in patients for whom pre-exposure smallpox vaccine is contraindicated (such as those with eczema or pregnant women), although it is currently not licensed in these cases. Two intravenous formulations of VIG (VIGIV Cangene and VIGIV Dynport) have been licensed by the FDA for the management of patients with progressive vaccinia, eczema vaccinatum, severe generalized vaccinia, and extensive body surface involvement or periocular implantation following inadvertent inoculation.
Institut de Biotechnologie, University of Lausanne, CH-1015 Lausanne, Switzerland. riccardo.wittek@unil.ch
Riccardo
R
Wittek
D023482:Bioterrorism; D006801:Humans; D017589:Immunization Programs / Q000458:organization & administration / Q000592:standards; D007116:Immunization, Passive / Q000379:methods / Q000592:standards; D016756:Immunoglobulins, Intravenous / Q000493:pharmacokinetics / Q000627:therapeutic use; D016730:Program Development; D012900:Smallpox Vaccine / Q000009:adverse effects*; D014615:Vaccinia / Q000517:prevention & control / Q000628:therapy*; D014616:Vaccinia virus / Q000276:immunology*
D016756:Immunoglobulins, Intravenous; D012900:Smallpox Vaccine